THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS








THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS


Santiago Moreno


University Hospital Ramón y CajalMadrid, Spain


None


ViiV board membership, consultancy and unrestricted grants.


23 April 2014


A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of all-cause mortality. We have recently described in long-term virally suppressed HIV infected subjects a negative correlation between the CD4/CD8 ratio and inflammation/inmmunosenescence. We also observed that is independently associated with surrogate markers of age-associated disease and non-AIDS-related morbidity and mortality. Collectively, these studies suggest that a low CD4/CD8 ratio despite otherwise effective ART might identify a new clinical phenotype of patients needed of novel interventions. Given the strong clinical implications of a novel and accessible diagnostic tool that might identify patients at higher risk of disease progression, the predictive importance of the CD4/CD8 ratio during treated HIV infection must be confirmed in large prospective studies. Five-year follow-up data on two large studies of maraviroc in treatment-experienced individuals with a registry of non-AIDS events have been reported, where the prognostic significance of the CD4/CD8 ratio during long-term ART can be conveniently addressed.



[{ "PostingID": 1402, "Title": "VIIV-A4001029", "Description": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Medicine: maraviroc, Condition: Infection, Human Immunodeficiency Virus, Phase: 2/3, Clinical Study ID: A4001029, Sponsor: ViiV" },{ "PostingID": 1403, "Title": "VIIV-A4001028", "Description": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Medicine: maraviroc, Condition: Infection, Human Immunodeficiency Virus, Phase: 2/3, Clinical Study ID: A4001028, Sponsor: ViiV" },{ "PostingID": 1404, "Title": "VIIV-A4001027", "Description": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Medicine: maraviroc, Condition: Infection, Human Immunodeficiency Virus, Phase: 2/3, Clinical Study ID: A4001027, Sponsor: ViiV" }]

Statistical Analysis Plan


Serrano-Villar S, Caruana G, Zlotnik A, Pérez-Molina JA, Moreno S. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy. 2017; 61(12). doi: 10.1128/AAC.01763-17.PMID: 28993335.